iBio, Inc. Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2016. The request metadata identifies “2015 Q3,” but the filing itself is the fiscal 2016 third-quarter Form 10-Q, filed May 23, 2016. Amounts are generally in thousands except per-share data.
Business Context
iBio is a biotechnology company commercializing plant-based protein expression technologies and developing biopharmaceutical candidates, including products for vaccines and fibrotic diseases. During the period, the company launched iBio CMO LLC, a contract manufacturing joint venture, with an affiliate of Eastern Capital Limited. Eastern contributed $15.0 million for a 30% interest; iBio retained 70% and contributed a royalty-bearing technology license.
Financial Performance and Position
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | $0.379 million vs. $0.349 million | $0.673 million vs. $1.535 million |
| Operating loss | $3.072 million vs. $1.688 million | $7.139 million vs. $4.770 million |
| Consolidated net loss | $3.385 million vs. $1.677 million | $7.436 million vs. $4.740 million |
| Net loss attributable to iBio | $3.036 million vs. $1.677 million | $7.087 million vs. $4.740 million |
| Loss per share | $0.04 vs. $0.02 | $0.09 vs. $0.07 |
| Operating cash flow | Not separately provided | $(5.250) million vs. $(3.518) million |
- Margins: Revenue remained small relative to costs. The operating loss equaled approximately 811% of quarterly revenue and 1,061% of nine-month revenue; comparable prior-year ratios were approximately 484% and 311%, respectively.
- Cash and liquidity: Cash was $21.893 million at March 31, 2016, compared with $9.494 million at June 30, 2015. Management expected cash on hand plus approximately $4.0 million received from Eastern in April 2016 to support operations at least through March 31, 2017.
- Debt and lease obligations: The capital lease obligation totaled $25.475 million, including $25.308 million long term. The obligation relates primarily to a 34-year sublease of an operating facility and equipment in Bryan, Texas, with minimum payments of $71.4 million, including $45.925 million of interest.
- Balance sheet: Total assets increased to $50.665 million from $12.494 million, primarily due to the capitalized facility and equipment. Total equity was $22.916 million, including $14.651 million of noncontrolling interest. Accumulated deficit was $54.914 million.
Material Changes Versus the Prior Comparable Period
- Quarterly revenue increased $30,000, or approximately 9%, but nine-month revenue declined $862,000, or approximately 56%, as the FioCruz yellow fever vaccine program neared completion and required less work.
- Quarterly general and administrative expense increased $1.181 million, primarily due to approximately $900,000 of iBio CMO-related costs. Nine-month general and administrative expense increased $1.935 million, including approximately $588,000 of higher legal costs and approximately $900,000 of iBio CMO costs.
- Quarterly research and development expense increased $233,000, while nine-month research and development expense decreased $428,000 due to changes in laboratory work and prior-period reconciliation items.
- Interest expense increased to $323,000 in the quarter and nine-month period because of the capital lease; prior-year periods had no such expense.
- Financing activities generated $17.662 million during the first nine months, including the $15.0 million iBio CMO capital contribution, $2.178 million from common stock sales, and $1.009 million from warrant exercises.
- Shares outstanding increased to 82.6 million at March 31, 2016 from 77.2 million at June 30, 2015. An additional 6.5 million shares were issued to Eastern in April 2016 for approximately $4.043 million.
Outlook, Risks, Contingencies, and Unusual Items
- Management planned to pursue additional technology licensing, product development, contract manufacturing, and technology-transfer opportunities through iBio CMO. Commercial operations at the Bryan, Texas facility commenced in January 2016.
- The company has incurred significant recurring losses and negative operating cash flow since its 2008 spin-off. Management stated that additional capital may be required for periods beyond December 31, 2016.
- Future funding may come from cash, additional equity or other securities, license and collaboration proceeds, and iBio CMO operations. No shares had been sold under the $15.0 million Aspire Capital facility as of the filing date. Additional equity financing could materially dilute existing shareholders.
- If funding is unavailable on acceptable terms, the company may need to delay, reduce, or discontinue development and commercialization activities, seek less favorable collaborations, dispose of technology rights, or potentially cease operations.
- The University of Pittsburgh fibrosis-license milestone requiring an FDA New Drug Application was extended from December 1, 2015 to June 1, 2016. The company and university expected to replace the milestone schedule based on technical and development changes.
- iBio’s litigation against Fraunhofer remained unresolved, and the company stated it could not predict the outcome. A securities class action settlement totaling $1.875 million was approved in April 2016 and funded by the insurance carrier. A separate derivative action remained pending.
- Related-party arrangements are material: Eastern affiliates provided the iBio CMO capital, facility sublease, and other services; Eastern also purchased company shares and exercised warrants.
- The company recognized no income tax expense and continued to maintain a valuation allowance against deferred tax assets.
Investor Verification Checklist
- Verify the sustainability and commercial economics of iBio CMO, including customer contracts, utilization of the Bryan facility, and the $2.1 million annual base rent plus minimum-sales provisions.
- Reconcile cash burn with management’s stated ability to fund operations through March 31, 2017, including the April 2016 Eastern proceeds.
- Assess the magnitude, terms, and potential dilution of future equity financing, including the Aspire Capital facility and the company’s shelf registration.
- Monitor progress on the FioCruz yellow fever vaccine program, the fibrosis product candidate, and the FDA-related development milestone.
- Review the Fraunhofer and derivative litigation, related-party transactions, and any changes to associated contingencies.
- Confirm Eastern’s ownership, governance rights, standstill provisions, and iBio’s continuing 70% interest in iBio CMO.